Inflammatory Bowel Disease Treatment Market by Drug Class (Aminosalicyclates, Immunomodulators, TNF Inhibitors, and Corticosteroids), Disease Indication (Crohn\'s Disease and Ulcerative Colitis), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026824 | Pages: 100 | Industry: Pharmaceuticals | Date: Oct 2022 | Type: Global

The market crossed US$ 21.30 billion in 2022 and is expected to hit US$ 31.27 billion by 2030, recording a CAGR of 4.9% during the forecast period

The crohn’s disease segment is expected to be growing due to its high prevalence rate

Crohn's disease is a type of inflammatory bowel disease (IBD). It causes tissue swelling in the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. According to the U.S. Department of Health and Human Services, researchers estimate that more than half a million people in the United States have Crohn’s disease. Studies show that Crohn’s disease has become more common in the United States and other parts of the world. Additionally, as of 2018, in Canada, the number of people with IBD is approximately 270,000 (0.7%). This number breaks down to 135,000 individuals living with Crohn’s disease and 120,000 with ulcerative colitis.

Within the report, the market is segmented into drug class, disease indication, distribution channel, and geography. Based on drug class, the global inflammatory bowel disease treatment market is segmented into aminosalicyclates, immunomodulators, TNF inhibitors, and corticosteroids. Based on disease indication, the market is bifurcated into crohn's disease and ulcerative colitis. By distribution channel, market segmentation is hospital pharmacy, online pharmacy, and retail pharmacy. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Increasing prevalence of irritable bowel syndrome and associated conditions

Inflammatory bowel disease (IBD) includes a group of related, chronic relapsing disorders. They significantly demand healthcare resources, including consultation time, testing, and treatment. CDC conducts multiple IBD studies each year to improve the understanding of the epidemiology and burden of IBD. As per the U.S. Department of Health & Human Services, the prevalence of IBD boosted from 2001 to 2018 among Medicare beneficiaries of all race and ethnicity groups, with the highest rate among non-Hispanic Black adults. The prevalence of IBD increased between 2006 and 2016 from 106.2 to 142.1, IBD cases per 10,000 patients, which is a 33.8% increase.

Increasing disposable incomes of the population

The size of the middle-class population will increase from 1.8 billion in 2009 to 3.2 billion by 2020 and 4.9 billion by 2030. Moreover, by 2030 Asia will represent 66% of the global middle-class population and 59% of middle-class consumption, compared to 28% and 23% in 2009. Additionally, the increasing prevalence of risk factors associated with inflammatory bowel disease is likely to drive the market. Increasing disposable income, introducing advanced medical devices, and emphasis on preventive care and diagnostic tests will offer significant opportunities for the inflammatory bowel disease market during the forecast period.

Recent strategic developments in the inflammatory bowel disease treatment market

The inflammatory bowel disease treatment market has undergone several significant developments, and a few of these have been mentioned below:

  • In May 2021, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD). It is an oral medication used once daily for patients with moderately to severely active UC
  • In July 2020, Takeda India, part of the Takeda Pharmaceutical Company, announced the expansion of its highly innovative portfolio for patients in the country with the launch of Kynteles (Vedolizumab) as part of its Gastrointestinal (GI) portfolio. Kynteles is used to treat adult patients with moderate to severely active ulcerative colitis (UC) and Crohn’s Disease (CD)

The inflammatory bowel disease treatment market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Pfizer Inc.; Novartis AG; Johnson & Johnson; AbbVie Inc; Takeda Pharmaceutical Company Limited; Allergan; Celgene Corporation; Bausch Health; UCB, Inc; Cosmo Pharmaceuticals are among the prominent players operating in the market.

The target audience for the report:

  • Raw Material Providers
  • Associations, Organizations, Forums, And Alliances
  • Government Bodies, Such as Regulating Authorities and Policymakers
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Venture Capitalists, Private Equity Firms, and Start-Up Companies
  • Research Institutes, Organizations, and Consulting Companies

Scope of the report:

In this report, the market has been segmented based on:

  • Drug Class:
  • Aminosalicyclates
  • Immunomodulators
  • TNF Inhibitors
  • Corticosteroids
  • Disease Indication:
  • Crohn's Disease
  • Ulcerative Colitis
  • Distribution Channel:
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • South & Central America
    • Middle East & Africa
  • Companies Profiled
    • Pfizer Inc.
    • Novartis AG
    • Johnson & Johnson
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • Allergan
    • Celgene Corporation
    • Bausch Health
    • UCB, Inc.
    • Cosmo Pharmaceuticals

The List of Companies
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Allergan
- Celgene Corporation
- Bausch Health
- UCB, Inc.
- Cosmo Pharmaceuticals

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000